Meclofenamic acid
Based on 9 publication(s) in Google Scholar
Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.66%
- CAS No.: 644-62-2
- Formula: C14H11Cl2NO2
- Molecular Weight:296.15
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Cytoskeleton Compound Library
HY-L060
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Potassium Channel Compound Library
HY-L119
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Meclofenamic acid
More- Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]
- Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]
- Sensor Actuat B-Chem. 2021, 129983.
- Biomater Adv. 2023 Nov:154:213634. [Abstract]
- Biochem Pharmacol. 2026 Apr:246:117710. [Abstract]
- PLoS Pathog. 2025 Jan 21;21(1):e1012895. [Abstract]
- Biomed Opt Express. 2021 Mar 9;12(4):1962-1973. [Abstract]
- Res Sq. 2026 Apr 6.
- SSRN. 2025 Jan 27.
Customer Validation & Images
-
WB
All Endogenous Metabolite Isoforms
More
Biological Activity
IC50: 1 μM (cyclooxygenase), 56.0 μM (hKv2.1), 155.9 μM (hKv1.1)[3]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
0.1 μM
Compound: 1a
|
Inhibition of Prostaglandin G/H synthase mediated PGF2-alpha formation in rat basophilic leukemia (RBL-1) cells
Inhibition of Prostaglandin G/H synthase mediated PGF2-alpha formation in rat basophilic leukemia (RBL-1) cells
|
[PMID: 8515419] |
| RBL-1 | IC50 |
0.1 μM
Compound: 1a (Meclofenamic acid)
|
Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-Cyclooxygenase
Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-Cyclooxygenase
|
10.1016/S0960-894X(00)80657-5 |
| RBL-1 | IC50 |
24 μM
Compound: 1a
|
Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
|
[PMID: 8515419] |
| RBL-1 | IC50 |
24 μM
Compound: 1a (Meclofenamic acid)
|
Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
|
10.1016/S0960-894X(00)80657-5 |
Meclofenamic acid (0-100 μM, 24 h) inhibits FTO demethylation in a dose-response manner[1].
Meclofenamic acid inhibits enzyme cyclooxygenase, with an IC50 about 1 μM, thereby inhibiting the production of prostaglandins[2].
Meclofenamic acid inhibits the release of 5-HETE and LTB4 from human neutrophils stimulated with calcium ionophore and antagonizes the response of tissues to certain prostaglandins[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa cells
-
Concentration:0, 12.5, 25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Inhibited FTO demethylation in a dose-response manner, and elevates the levels of cellular m6A in mRNA by targeting FTO.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 644-62-2
-
Appearance Solid
-
Molecular Weight 296.15
-
Formula C14H11Cl2NO2
-
Color White to yellow
-
SMILES
O=C(O)C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl
-
Synonyms
Meclofenamate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cancer Commun (Lond)
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm. [Abstract]2025 May;45(5):608-631. PMID: 39960839 -
Theranostics
2021 Jul 25;11(17):8464-8479. PMID: 34373753
Meclofenamic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]
The effect of FTO inhibitor Meclofenamate sodium (MS) (80 μM and 120 μM) on ATF4 protein expression and mTORC1 activity during 968 treatment is detected by western blotting. MS efficiently reduces ATF4 expression and rescues the mTOR downregulation induced by compound 968.
-
-
Biomater Adv
Anti-resorption role of low-intensity pulsed ultrasound (LIPUS) during large-scale bone reconstruction using porous titanium alloy scaffolds through inhibiting osteoclast differentiation. [Abstract]2023 Nov:154:213634. PMID: 37783002 -
Biochem Pharmacol
Inhibition of Ca2+-activated chloride channels by the NSAID meclofenamate for anti-diarrhea. [Abstract]2026 Apr:246:117710. PMID: 41544862 -
PLoS Pathog
Pseudorabies virus infection triggers pUL46-mediated phosphorylation of connexin-43 and closure of gap junctions to promote intercellular virus spread. [Abstract]2025 Jan 21;21(1):e1012895. PMID: 39836710 -
Biomed Opt Express
Investigating tunneling nanotubes in ovarian cancer based on two-photon excitation FLIM-FRET. [Abstract]2021 Mar 9;12(4):1962-1973. PMID: 33996210 -
-
Solvent & Solubility
DMSO : 100 mg/mL (337.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Methanol : 7.14 mg/mL (24.11 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huang Y, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015 Jan;43(1):373-84. [Content Brief]
[2]. Conroy MC, et al. Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. [Content Brief]
[3]. Lee YT, et al. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol. 1999 Aug 13;378(3):349-56. [Content Brief]
[4]. Eleftheriou CG, et al. Meclofenamic acid improves the signal to noise ratio for visual responses produced by ectopicexpression of human rod opsin. Mol Vis. 2017 Jun 16;23:334-345. eCollection 2017. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Methanol / DMSO | 1 mM | 3.3767 mL | 16.8833 mL | 33.7667 mL | 84.4167 mL |
| 5 mM | 0.6753 mL | 3.3767 mL | 6.7533 mL | 16.8833 mL | |
| 10 mM | 0.3377 mL | 1.6883 mL | 3.3767 mL | 8.4417 mL | |
| 15 mM | 0.2251 mL | 1.1256 mL | 2.2511 mL | 5.6278 mL | |
| 20 mM | 0.1688 mL | 0.8442 mL | 1.6883 mL | 4.2208 mL | |
| DMSO | 25 mM | 0.1351 mL | 0.6753 mL | 1.3507 mL | 3.3767 mL |
| 30 mM | 0.1126 mL | 0.5628 mL | 1.1256 mL | 2.8139 mL | |
| 40 mM | 0.0844 mL | 0.4221 mL | 0.8442 mL | 2.1104 mL | |
| 50 mM | 0.0675 mL | 0.3377 mL | 0.6753 mL | 1.6883 mL | |
| 60 mM | 0.0563 mL | 0.2814 mL | 0.5628 mL | 1.4069 mL | |
| 80 mM | 0.0422 mL | 0.2110 mL | 0.4221 mL | 1.0552 mL | |
| 100 mM | 0.0338 mL | 0.1688 mL | 0.3377 mL | 0.8442 mL |
Meclofenamic acid Related Classifications
HY-117275 Related Classifications
Powered by Bioz